Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-01-17
2006-01-17
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C548S530000, C548S201000, C548S123000, C548S124000, C548S127000, C548S128000, C548S131000, C548S200000, C548S135000, C548S136000, C548S143000, C548S182000, C548S206000, C548S215000, C548S262200, C548S300100, C548S311100, C548S356100, C548S364100, C548S366400, C548S363100, C548S326100, C548S360500, C548S373100, C548S371400, C548S401000, C548S559000, C548S208000
Reexamination Certificate
active
06987104
ABSTRACT:
N-[1-oxo-(optionally 2-aza)-2-alkyl-3-(carboxyl or thiol or hydroxyaminocarbonyl or N-hydroxyformamido)-propyl]-(aryl or heteroaryl)-azacyclo4-7alkanes or thiazacyclo4-7alkanes, salts or prodrugs thereof have interesting properties, e.g., in the treatment or prevention of disorders amenable to treatment by PDF inhibitors, such as treatment of bacterial infections.
REFERENCES:
patent: 4052511 (1977-10-01), Cushman et al.
patent: 4290952 (1981-09-01), Freed et al.
patent: 4303662 (1981-12-01), Sprague
patent: 4311705 (1982-01-01), Ondetti et al.
patent: 4320057 (1982-03-01), Freed et al.
patent: 4321383 (1982-03-01), Sprague
patent: 4599361 (1986-07-01), Dickens et al.
patent: 4804676 (1989-02-01), Inaoka et al.
patent: 5128346 (1992-07-01), Nadzan et al.
patent: 5256657 (1993-10-01), Singh et al.
patent: 5268384 (1993-12-01), Galardy
patent: 5447929 (1995-09-01), Broadhurst et al.
patent: 5453423 (1995-09-01), Long et al.
patent: 5552419 (1996-09-01), MacPherson et al.
patent: 5614625 (1997-03-01), Broadhurst et al.
patent: 5643908 (1997-07-01), Sugimura et al.
patent: 5712300 (1998-01-01), Jacobsen
patent: 5869518 (1999-02-01), Bedoya Zurita et al.
patent: 5876727 (1999-03-01), Swain et al.
patent: 236 872 (1987-09-01), None
patent: 274 453 (1988-07-01), None
patent: 334 244 (1989-09-01), None
patent: 423 943 (1991-04-01), None
patent: 489 577 (1992-06-01), None
patent: 489 579 (1992-06-01), None
patent: 497 192 (1992-08-01), None
patent: 574 758 (1993-12-01), None
patent: WO 90/05716 (1990-05-01), None
patent: WO 90/05719 (1990-05-01), None
patent: WO 91/02716 (1991-03-01), None
patent: WO 92/13831 (1992-08-01), None
patent: WO 92/22523 (1992-12-01), None
patent: WO 93/09090 (1993-05-01), None
patent: WO 93/09097 (1993-05-01), None
patent: WO 93/20047 (1993-10-01), None
patent: WO 93/24449 (1993-12-01), None
patent: WO 93/24475 (1993-12-01), None
patent: WO 94/02446 (1994-02-01), None
patent: WO 94/02447 (1994-02-01), None
patent: WO 94/21612 (1994-09-01), None
patent: WO 94/25434 (1994-11-01), None
patent: WO 94/25435 (1994-11-01), None
patent: WO 95/33731 (1995-12-01), None
patent: WO 96/25156 (1996-08-01), None
patent: WO 96/26918 (1996-09-01), None
patent: WO 97/30707 (1997-08-01), None
patent: WO 97/49674 (1997-12-01), None
patent: WO 98/55449 (1998-12-01), None
patent: WO 99/02510 (1999-01-01), None
patent: WO 99/39704 (1999-08-01), None
patent: WO 01/44178 (2001-06-01), None
patent: WO 02/28829 (2002-04-01), None
Bord et al., “Stromelysin-1 (MMP-3) and Stromelysin-2 (MMP-10) Expression in Developing Human Bone: Potential Roles in Skeletal Development”, Bone, vol. 23, No. 1, pp. 7-12 (1998).
Chang et al., “Methlonine Aminopeptidase Gene ofEscherichia coliIs Essential for Cell Growth”, J. Bacteriol., vol. 171, No. 7, pp. 4071-4072 (1989).
Durand et al., “Peptide Aldehyde Inhibitors of Bacterial Peptide Deformylases”, Arch. Biochem. Biophys., vol. 367, No. 2, pp. 297-302 (1999).
Gearing et al., “Processing of Tumour Necrosis Factor-α Precursor by Metalloproteinasis”,Nature, vol. 370, pp. 555-557 (1994).
Hao et al., “Structural Basis for the Design of Antibiotics Targeting Peptide Deformylase”,Biochemistry, vol. 38, No. 15, pp. 4712-4719 (1999).
Hu et al., “H-Phosphonate Derivatives as Novel Peptide Deformylase Inhibitors”,Bioorg. Med. Chem. Letts., vol. 8, pp. 2479-2482 (1998).
Izquierdo-Martin et al., “Mechanistic Studies on the Inhibition of Thermolysin by a Peptide Hydroxamic Acid”,J. Am. Chem. Soc., vol. 114, No. 1, pp. 325-331 (1992).
Liu et al., “Distinct Expression of Gelatinase A [Matrix Metalloproteinase (MMP)-2], Collagenase-3 (MMP-13), Membrane Type MMP 1 (MMP-14), and Tissue Inhibitor of MMPs Type 1 Mediated by Physiological Signals During Formation and Regression of the Rat Corpus Luteum”,Endocrinology, vol. 140, No. 11, pp. 5330-5338 (1999).
Mazel et al., Genetic Characterization of Polypeptide Deformylase, a Distinctive Enzyme of Eubacterial Translation,EMBO J., vol. 13, No. 4, pp. 914-923.
McGeehan et al., “Regulation of Tumour Necrosis Factor-a Processing by a Metalloproteinase Inhibitor”,Nature, vol. 370, pp. 558-561 (1994).
Meinnel et al., “Characterization of theThermus thermophilusLocus Encoding Peptide Deformylase and Methionyl-tRNA1MetFormyltransferase”,J. Bacteriol., vol. 176, No. 23, pp. 7387-7390 (1994).
Meinnel et al., “Structure-Function Relationships within the Peptide Deformylase Family. Evidence for a Conserved Architecture of the Active Site Involving Three Conserved Motifs and a Metal Ion”,J. Mol. Biol., vol. 267, pp. 749-761 (1997).
Meinnel et al., “Design and Synthesis of Substrate Analogue Inhibitors of Peptide Deformylase”,Biochemistry, vol. 38, No. 14, pp. 4287-4295 (1999).
Mohler et al., “Protection Against a Lethal Dose of Endotoxin by an Inhibitor of Tumour Necrosis Factor Processing”,Nature, vol. 370, pp. 218-220 (1994).
O'Connell et al., “A High Quality Nuclear Magnetic Resonance Solution Structure of Peptide Deformylase fromEscherichia coli: Application of an Automated Assignment Strategy Using GARANT”,J. Biomol. NMR, vol. 13, No. 4, pp. 311-324 (1999).
Rajagopalan et al., “Purification, Characterization, and Inhibition of Peptide Deformylase fromEscherichia coli”, Biochemistry, vol. 36, No. 45, pp. 13910-13918 (1997).
Yamagiwa et al., “Expression of Metalloproteinase-13 (Collagenase-3) Is Induced During Fracture Healing in Mice”,Bone, vol. 25, No. 2, pp. 197-203 (1999).
Jacobs Jeffrey
Jain Rakesh K.
Lewis Jason G.
Patel Dinesh V.
Yuan Zhengyu
Savitsky Thomas R.
Vicuron Pharmaceuticals Inc.
Ward Paul V
Wilson James O.
LandOfFree
Pyrrolidine bicyclic compounds and its derivatives,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrrolidine bicyclic compounds and its derivatives,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrolidine bicyclic compounds and its derivatives,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3568682